TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
TORONTO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
Partnership Underway to Develop Extensive Protocols and Submissions for US Food & Drug Administration to...
TORONTO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly...
Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused...
Licensed Producers and Multi-State Operators are recognizing the volumes of data they hold from production...
TORONTO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
TORONTO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
TORONTO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a...
CB2 Insights’ Q3 2019 preliminary unaudited revenue saw a sequential growth of approximately 29% compared to...
Partnership to focus on implementing a medical product development strategy for VIVO’s global medical cannabis...
Support
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads